skip to content

A story of ups and downs for a Cambridge drug for multiple sclerosis

Thursday 10 March: 6:00pm - 7:30pm

Mill Lane Lecture Rooms , 8 Mill Lane, CB2 1RW

Scientists, doctors and patients describe the bumpy journey of a drug developed in Cambridge in the 1980s as Campath-1H (Cambridge Pathology antibody number 1) that was finally approved by the National Centre for Clinical Excellence in 2014 as a treatment for multiple sclerosis.

• Alasdair Coles (Professor of Neuroimmunology, Neurologist, University of Cambridge)
• Herman Waldmann (Emeritus Professor of Pathology, University of Oxford)
• Geoff Hale (Emeritus Professor of Therapeutic Immunology, University of Oxford)
• Alastair Compston (Emeritus Professor of Neurology, University of Cambridge)
• Helen Burchmore (Person affected by multiple sclerosis, patient expert at the NICE HTA Committee meetings for Alemtuzumab)
• Sybil Stacpoole (Consultant Neurologist, Addenbrooke’s Hospital, Cambridge)

Booking Information

Telephone number:
01223 766766

Booking required


Full access

Additional Information

Talk, Arrive on time, Free